Researchers posit that the influence of gut microbiota extends to the brain via neuroinflammation,
Neuropathic pain has been linked with negative outcomes including psychological distress.
Investigators examined antibiotic use in patients with bipolar disorder, schizophrenia, and major depressive disorder.
These data substantiate claims that certain neuroinflammatory biomarkers may predict depression symptoms or severity and could be useful in developing diagnostic and treatment strategies.
Researchers found a small number of clinical trials that indicated antidepressant effects of cytokine blockers.
Abnormal CRP levels appear to be a biomarker of both major depression and non-remission with antidepressant treatment in individuals with schizophrenia but not in those with unipolar disorder.
Neuroimaging studies have shown several neurophysiological substrates for depression: An overview by Theodore Henderson, MD, PhD.
Results from animal studies have been showing that anesthetics may be neurotoxic and could lead to cognitive dysfunction.
Patients commonly report inter-episodic cognitive complaints during the "remitted" phases of depression that negatively affect their ability to engage in more cognitively demanding activities.
As depression is one of the most common psychiatric disorders following acute stroke and can be predictive of poor outcomes, identifying biomarkers to recognize the disorder are imperative for improving the clinical course.